Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?

Br J Dermatol. 2007 Jan;156(1):57-61. doi: 10.1111/j.1365-2133.2006.07559.x.

Abstract

Background: Patients with mycosis fungoides (MF) experience frequent disease recurrences following total skin electron irradiation (TSEI) and may benefit from adjuvant therapy.

Objectives: To review the McGill experience with adjuvant alpha-interferon (IFN) in the treatment of MF.

Methods: From 1990 to 2000, 50 patients with MF were treated with TSEI: 31 with TSEI alone and 19 with TSEI + IFN. Median TSEI dose was 35 Gy. In the TSEI + IFN group, IFN was given subcutaneously at 3 x 10(6) units three times per week starting 2 weeks prior to start of TSEI, continued concurrently with the radiation and for an additional 12 months following TSEI. The TSEI alone group included 16 men and 15 women with a median age of 61 years (range 31-84). The TSEI + IFN group included 14 men and five women with a median age of 51 years (range 24-83). Clinical stage was IA, IB, IIA, IIB, III and IVA in 2, 9, 4, 8, 1 and 7 patients of the TSEI group and 0, 3, 3, 7, 4 and 2 patients of the TSEI + IFN group.

Results: Median follow up for living patients was 70 months. All patients responded to treatment. Complete response (CR) rate was 65% following TSEI and 58% following TSEI + IFN (P = 0.6). Median overall survival (OS) was 61 months following TSEI and 38 months following TSEI + IFN (P = 0.4). Acute grade II-III dermatitis was seen in all patients. Fever, chills or myalgia were seen in 32% of patients treated with TSEI + IFN.

Conclusions: Concurrent IFN and TSEI is feasible, with acceptable toxicity. Even when controlling for disease stage, the addition of IFN did not appear to increase CR rate, disease-free survival or OS.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant / methods
  • Cohort Studies
  • Combined Modality Therapy / methods
  • Disease-Free Survival
  • Drug Eruptions / etiology
  • Female
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Middle Aged
  • Mycosis Fungoides / drug therapy*
  • Mycosis Fungoides / radiotherapy*
  • Neoplasm Recurrence, Local
  • Recombinant Proteins
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / radiotherapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Interferon Type I
  • Recombinant Proteins